Scientists wire up pelvic nerves to decode bladder and bowel disorders
NCT ID NCT05200923
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to collect electrical signals from the body in people with overactive bladder, fecal incontinence, or urinary retention who are receiving sacral neuromodulation therapy. Researchers will gather data at several time points during the evaluation period to better understand how the therapy affects nerve signals. The study involves 300 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sacral neuromodulation device
- What this could lead to
- If successful, this could improve understanding of how sacral neuromodulation works, potentially leading to better therapies for pelvic health conditions.
- What could go wrong
- This is an observational data-collection study, not a treatment trial. It is early-stage and may not directly lead to new treatments or benefits for participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Overactive Bladder Criteria Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation 6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary. 7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Non-Obstructive Urinary Retention Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Fecal Incontinence Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling) Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Exclusion Criteria: Overactive Bladder Criteria Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component 8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 12. Women who are pregnant or planning to become pregnant 13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Non-Obstructive Urinary Retention Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 10. Women who are pregnant or planning to become pregnant 11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Fecal Incontinence Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. Have uncorrected high grade internal rectal prolapse 6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 9. Women who are pregnant or planning to become pregnant 10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fecal incontinence are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
DHR Health Institute for Research and Development
COMPLETEDEdinburg, Texas, 78539, United States
-
Indiana University Health Methodist Research Institute
RECRUITINGIndianapolis, Indiana, 46202, United States
-
LSUHSC Department of Urology
WITHDRAWNNew Orleans, Louisiana, 70112, United States
-
Mayo Clinic Urology/Urogynecology Department
RECRUITINGRochester, Minnesota, 55905, United States
-
Ochsner Clinic Foundation
RECRUITINGNew Orleans, Louisiana, 70121, United States
-
OhioHealth Physician's Group Urology
RECRUITINGHilliard, Ohio, 43026-2050, United States
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Prostate drug tested to stop urinary problems after rectal surgery
- Can a simple device stop enema leaks for spina bifida patients?
- Could simple exercises restore pelvic health after cervical cancer?
- Can a magnetic chair ease bowel leakage after J-Pouch surgery?
- Diabetes drug class may change how the bladder behaves
- New catheter design aims to make Self-Catheterization easier and more comfortable